NYSE:AGN - Allergan Stock Price, Price Target & More

$158.51 -0.08 (-0.05 %)

(As of 04/22/2018 02:46 AM ET)

Previous Close$158.51

Today's Range$157.28 - $161.15

52-Week Range$142.81 - $256.80

Volume3.18 million shs

Average Volume2.51 million shs

Market Capitalization$55.24 billion

P/E Ratio9.69

Dividend Yield1.82%

Beta1.18

About Allergan (NYSE:AGN)

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNYSE:AGN

CUSIP01849010

Webwww.allergan.com

Phone353-1435-7700

Debt

Debt-to-Equity Ratio0.38%

Current Ratio1.16%

Quick Ratio1.06%

Price-To-Earnings

Trailing P/E Ratio9.69

Forward P/E Ratio10.17

P/E Growth1.13

Sales & Book Value

Annual Sales$15.94 billion

Price / Sales3.46

Cash Flow$40.1291 per share

Price / Cash3.95

Book Value$207.19 per share

Price / Book0.77

Profitability

EPS (Most Recent Fiscal Year)$16.35

Net Income$-4,125,500,000.00

Net Margins-26.32%

Return on Equity8.43%

Return on Assets4.75%

Miscellaneous

Employees17,800

Outstanding Shares348,340,000

How to Become a New Pot Stock Millionaire

Allergan (NYSE:AGN) Frequently Asked Questions

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan declared a quarterly dividend on Friday, February 9th. Shareholders of record on Wednesday, February 28th will be given a dividend of $0.72 per share on Wednesday, March 28th. This represents a $2.88 annualized dividend and a yield of 1.82%. The ex-dividend date of this dividend is Tuesday, February 27th. This is an increase from Allergan's previous quarterly dividend of $0.70. View Allergan's Dividend History.

How will Allergan's stock buyback program work?

Allergan announced that its Board of Directors has approved a share repurchase plan on Tuesday, September 26th 2017, which authorizes the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 2.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's leadership believes its shares are undervalued.

How were Allergan's earnings last quarter?

Allergan (NYSE:AGN) posted its quarterly earnings results on Tuesday, February, 6th. The company reported $4.86 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $4.74 by $0.12. The firm earned $4.33 billion during the quarter, compared to analyst estimates of $4.28 billion. Allergan had a positive return on equity of 8.43% and a negative net margin of 26.32%. The firm's quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.90 EPS. View Allergan's Earnings History.

When is Allergan's next earnings date?

Allergan is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Allergan.

What guidance has Allergan issued on next quarter's earnings?

Allergan issued an update on its FY18 earnings guidance on Tuesday, February, 6th. The company provided EPS guidance of $15.25-16.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.42. The company issued revenue guidance of $15.0-15.3 billion, compared to the consensus revenue estimate of $15.25 billion.Allergan also updated its Q1 guidance to $3.20-3.40 EPS.

What price target have analysts set for AGN?

21 brokerages have issued 12-month price objectives for Allergan's stock. Their predictions range from $160.07 to $265.00. On average, they expect Allergan's share price to reach $220.9035 in the next twelve months. View Analyst Ratings for Allergan.

What are Wall Street analysts saying about Allergan stock?

Here are some recent quotes from research analysts about Allergan stock:

1. Cantor Fitzgerald analysts commented, "Key takeaways from the quarter: 1) AGN has more important pipeline catalysts in 2018 including those for the CGRPs for migraine, abicipar for AMD, and the FDA approval of Esmya. 2) LOEs and mix will impact AGN’s margins in the near term, but its cost-cutting initiatives will buffer the impact with longer- term margin expansion driven by pipeline success. 3) ~One-third of AGN’s sales comes from cash pay products and Botox Therapeutics, and AGN believes this will grow to ~45% of sales by 2022. 4) Capital allocation strategy is sound with AGN on its way to achieving a 3x leverage ratio, and maintaining its investment grade rating, AGN will be opportunistic on its $2B share buyback and is committed to growing its dividend. 5) As of 12/31/17, AGN had cash & equivalents of $6.5B and debt of $30.1B, CFLO from operations increased to ~$2.1B in 4Q17. 6) Top line results from ACHIEVE I (UBR-MD-01) study demonstrated efficacy, safety and tolerability, study met co-primary endpoints in the first of two Phase 3 studies, there were 6 cases with aminotransferase (ALT or AST) elevations greater than 3x the upper limit of normal, and there were alternative explanations in all cases." (2/6/2018)
2. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar support sales. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, it is facing potential loss of exclusivity for many products in 2018 including Namenda XR and Restasis. In October 2017, a Texas federal district court invalidated four of the six patents covering Restasis, potentially opening doors for early generic competition. Though Restasis patents are scheduled to expire in August 2024, a generic version may be launched as early as mid-2018. Also, new competition for key growth drivers, Restasis and Linzess, is an investor concern. Allergan’s shares underperformed the industry in the past six months. " (1/2/2018)

Are investors shorting Allergan?

Allergan saw a drop in short interest during the month of March. As of March 15th, there was short interest totalling 6,391,424 shares, a drop of 39.1% from the February 28th total of 10,501,103 shares. Based on an average daily volume of 4,617,063 shares, the short-interest ratio is presently 1.4 days. Approximately 1.9% of the shares of the company are sold short.

Who are some of Allergan's key competitors?

Some companies that are related to Allergan include Abbott Laboratories (ABT), Bayer (BAYRY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Mylan (MYL) and Teva Pharmaceutical Industries (TEVA).

Who are Allergan's key executives?

Allergan's management team includes the folowing people:

Mr. Brenton L. Saunders, Chairman, Chief Exec. Officer and Pres (Age 48)
Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 50)
Mr. Matthew M. Walsh, Exec. VP & CFO (Age 51)
Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 50)
Mr. James C. D'Arecca, Chief Accounting Officer (Age 47)

Has Allergan been receiving favorable news coverage?

Media coverage about AGN stock has trended somewhat positive on Sunday, according to Accern. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Allergan earned a news sentiment score of 0.19 on Accern's scale. They also assigned news coverage about the company an impact score of 45.96 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Allergan?

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $158.51.

How big of a company is Allergan?

Allergan has a market capitalization of $55.24 billion and generates $15.94 billion in revenue each year. The company earns $-4,125,500,000.00 in net income (profit) each year or $16.35 on an earnings per share basis. Allergan employs 17,800 workers across the globe.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 353-1435-7700 or via email at [email protected]

MarketBeat Community Rating for Allergan (AGN)

Community Ranking:		3.4 out of 5 ( )
Outperform Votes:		1,003 (Vote Outperform)
Underperform Votes:		458 (Vote Underperform)
Total Votes:		1,461

MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Allergan (NYSE:AGN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

21 Wall Street analysts have issued ratings and price targets for Allergan in the last 12 months. Their average twelve-month price target is $220.9035, suggesting that the stock has a possible upside of 39.36%. The high price target for AGN is $265.00 and the low price target for AGN is $160.07. There are currently 7 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.67	2.70	2.61	2.60
Ratings Breakdown:	0 Sell Rating(s) 7 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 7 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 8 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$220.9035	$223.7405	$227.1294	$251.9444
Price Target Upside:	39.36% upside	33.93% upside	20.72% upside	33.81% upside

Allergan (NYSE:AGN) Consensus Price Target History

Price Target History for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/17/2018	Stifel Nicolaus	Initiated Coverage	Hold -> Hold	$192.00	Low
4/16/2018	Cowen	Set Price Target	Buy	$255.00	Low
4/12/2018	Cantor Fitzgerald	Set Price Target	Hold	$191.00	Low
4/12/2018	Deutsche Bank	Reiterated Rating	Buy		Low
3/26/2018	Leerink Swann	Reiterated Rating	Outperform		High
3/15/2018	JPMorgan Chase	Set Price Target	Buy	$265.00	Low
3/14/2018	Royal Bank of Canada	Reiterated Rating	Buy	$213.00	Low
3/1/2018	Credit Suisse Group	Set Price Target	Buy	$215.00	Low
3/1/2018	Morgan Stanley	Lower Price Target	Overweight -> Overweight	$200.00 -> $181.00	High
2/23/2018	SunTrust Banks	Initiated Coverage	Buy -> Buy	$200.00	Low
2/7/2018	Bank of America	Boost Price Target	Buy -> Buy	$208.00 -> $215.00	Low
1/29/2018	Barclays	Upgrade	Equal Weight -> Overweight	$220.00 -> $230.00	Low
1/10/2018	UBS	Set Price Target	Buy	$250.00	Medium
1/9/2018	Citigroup	Lower Price Target	Buy	$215.00	N/A
1/5/2018	Wells Fargo	Set Price Target	Buy	$245.00	Low
12/7/2017	Argus	Downgrade	Buy -> Hold	$256.80 -> $160.07	Low
10/19/2017	Mizuho	Downgrade	Buy -> Neutral	$193.00 -> $193.00	N/A
10/18/2017	Edward Jones	Reiterated Rating	Buy -> Hold		N/A
10/18/2017	Sanford C. Bernstein	Set Price Target	Buy	$296.00 -> $252.00	N/A
10/13/2017	Piper Jaffray	Set Price Target	Hold	$227.00	N/A
5/10/2017	Goldman Sachs	Downgrade	Buy -> Neutral	$262.00	High
11/21/2016	William Blair	Reiterated Rating	Market Perform		N/A

(Data available from 4/22/2016 forward)

Allergan (NYSE:AGN) Earnings History and Estimates Chart

Earnings by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Earnings Estimates

2018 EPS Consensus Estimate: $15.48

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$3.37	$3.39	$3.38
Q2 2018	3	$3.17	$3.92	$3.67
Q3 2018	3	$3.85	$3.89	$3.87
Q4 2018	3	$4.39	$4.81	$4.56

Allergan (NYSE AGN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/30/2018		$3.39					N/A
2/6/2018	Q4 2017	$4.74	$4.86	$4.2813 billion	$4.3261 billion	View	Listen
11/1/2017	Q3 2017	$4.06	$4.15	$4.0377 billion	$4.0340 billion	View	N/A
8/3/2017	Q2 2017	$3.95	$4.02	$3.9461 billion	$4.0074 billion	View	Listen
5/9/2017	Q1 2017	$3.32	$3.35	$3.5325 billion	$3.5730 billion	View	Listen
2/8/2017	Q416	$3.76	$3.90	$3.77 billion	$3.86 billion	View	Listen
11/2/2016	Q316	$3.57	$3.32	$3.73 billion	$3.62 billion	View	Listen
8/8/2016	Q216	$3.34	$3.35	$4.10 billion	$3.68 billion	View	Listen
5/10/2016	Q116	$3.03	$3.04	$3.97 billion	$3.80 billion	View	Listen
2/22/2016	Q415	$3.36	$3.41	$4.20 billion	$4.20 billion	View	Listen
11/4/2015	Q315	$3.20	$3.48	$5.71 billion	$4.10 billion	View	N/A
8/6/2015	Q215	$4.41	$4.41	$5.71 billion	$5.76 billion	View	N/A
5/11/2015	Q115	$3.84	$4.30	$4.04 billion	$4.23 billion	View	Listen
2/18/2015	Q414	$3.67	$3.91	$3.84 billion	$4.01 billion	View	N/A
11/5/2014	Q414	$1.83	$2.17	$1.9018 billion	$1.9105 billion	View	N/A
11/5/2014	Q314	$3.10	$3.19	$3.63 billion	$3.68 billion	View	N/A
8/5/2014	Q314	$1.76	$1.78	$1.78 billion	$1.79 billion	View	Listen
8/5/2014	Q214	$3.36	$3.42	$2.55 billion	$2.67 billion	View	N/A
7/21/2014	Q214	$1.44	$1.51	$1.77 billion	$1.83 billion	View	N/A
4/30/2014	Q114	$1.13	$1.18	$1.60 billion	$1.6460 billion	View	N/A
4/30/2014	Q114	$3.23	$3.49	$2.59 billion	$2.66 billion	View	Listen
2/20/2014	Q413	$3.05	$3.17	$2.68 billion	$2.78 billion	View	Listen
2/4/2014	Q413	$1.34	$1.12	$1.65 million	$1.66 million	View	N/A
10/29/2013	Q313	$1.20	$1.23	$1.53 billion	$1.23 billion	View	Listen
10/29/2013	Q313	$2.09	$2.09	$2.04 billion	$2.01 billion	View	Listen
7/31/2013	Q2 2013	$1.20	$1.22	$1.56 billion	$1.5977 billion	View	N/A
7/25/2013	Q2 2013	$2.00	$2.01	$1.9857 billion	$1.9898 billion	View	Listen
5/2/2013	Q1 2013	$1.86	$1.99	$1.97 billion	$1.90 billion	View	Listen
5/1/2013	Q1 2013	$0.96	$0.98	$1.44 billion	$1.46 billion	View	N/A
2/19/2013	Q4 2012	$1.53	$1.59	$1.74 million	$1.75 billion	View	Listen
2/5/2013	Q4 2012	$1.20	$1.15	$1.51 million	$1.48 million	View	N/A
10/30/2012	Q312	$1.04	$1.06	$1.43 billion	$1.39 billion	View	N/A
8/1/2012		$1.06	$1.07			View	N/A
5/2/2012		$0.87	$0.86			View	N/A
2/14/2012	Q4 2011	$1.75	$1.77			View	N/A
2/2/2012		$1.00	$1.00			View	N/A
10/26/2011		$0.90	$0.92			View	N/A
8/3/2011		$0.95	$0.96			View	N/A
7/26/2011	Q2 2011	$1.00	$1.01			View	N/A
5/4/2011		$0.74	$0.77			View	N/A
2/15/2011	Q4 2010	$0.93	$0.93			View	N/A
2/2/2011		$0.89	$0.88			View	N/A
11/4/2010	Q3 2010	$0.84	$0.85			View	N/A
8/5/2010	Q2 2010	$0.81	$0.83			View	N/A
5/10/2010	Q1 2010	$0.74	$0.63			View	N/A
2/23/2010	Q4 2009	$0.72	$0.85			View	N/A
11/4/2009	Q3 2009	$0.65	$0.66			View	N/A
7/29/2009	Q2 2009	$0.57	$0.61			View	N/A
4/30/2009	Q1 2009	$0.49	$0.58			View	N/A
2/19/2009	Q4 2008	$0.50	$0.53			View	N/A
10/29/2008	Q3 2008	$0.46	$0.48			View	N/A
8/6/2008	Q2 2008	$0.48	$0.48			View	N/A
5/1/2008	Q1 2008	$0.51	$0.55			View	N/A
2/20/2008	Q4 2007	$0.31	$0.35			View	N/A

(Earnings results data provided by Zacks Investment Research)

Allergan (NYSE:AGN) Dividend Information

Allergan pays an annual dividend of $2.88 per share, with a dividend yield of 1.82%. AGN's most recent quarterly dividend payment was Wednesday, March 28. Allergan pays out 17.61% of its earnings out as a dividend.

Most Recent Dividend:	3/28/2018
Annual Dividend:	$2.88
Dividend Yield:	1.82%
Dividend Growth:	141.00% (3 Year Average)
Payout Ratio:	17.61% (Trailing 12 Months of Earnings) 18.47% (Based on This Year's Estimates) 17.42% (Based on Next Year's Estimates)
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/9/2018	quarterly	$0.72	1.71%	2/27/2018	2/28/2018	3/28/2018
10/27/2017	quarterly	$0.70	1.58%	11/16/2017	11/17/2017	12/15/2017
8/2/2017	Quarterly	$0.70	1.12%	8/16/2017	8/18/2017	9/15/2017
5/5/2017	quarterly	$0.70	0.01%	5/16/2017	5/18/2017	6/15/2017
11/2/2016	quarterly	$0.70		2/24/2017	2/28/2017	3/28/2017
2/4/2015	quarterly	$0.05	0.09%	2/5/2015	2/9/2015	3/20/2015
10/27/2014	quarterly	$0.05			11/20/2014	12/11/2014
7/28/2014	quarterly	$0.05	0.12%	8/13/2014	8/15/2014	9/5/2014
5/7/2014	quarterly	$0.05	0.12%	5/21/2014	5/23/2014	6/13/2014
2/5/2014	quarterly	$0.05	0.17%	2/26/2014	2/28/2014	3/21/2014
10/30/2013	quarterly	$0.05	0.22%	11/18/2013	11/20/2013	12/11/2013
7/31/2013	quarterly	$0.05	0.22%	8/20/2013	8/22/2013	9/12/2013
5/2/2013	quarterly	$0.05	0.2%	5/21/2013	5/23/2013	6/13/2013
2/6/2013	quarterly	$0.05	0.18%	2/26/2013	2/28/2013	3/21/2013

(Data available from 1/1/2013 forward)

Allergan (NYSE AGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.36%
Institutional Ownership Percentage: 77.95%

Insider Trading History for Allergan (NYSE:AGN)

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE AGN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2018	Maria Teresa Hilado	Insider	Buy	895	$167.39	$149,814.05
3/8/2018	Brent L. Saunders	CEO	Buy	3,300	$152.53	$503,349.00
3/8/2018	Matthew M. Walsh	CFO	Buy	1,000	$153.96	$153,960.00
3/5/2018	Joseph H. Boccuzi	Director	Buy	900	$143.42	$129,078.00
2/21/2018	Matthew M Walsh	CFO	Buy	2,000	$160.94	$321,880.00
2/14/2018	William Meury	Insider	Sell	58,879	$160.62	$9,457,144.98
12/7/2017	Chris W. Bodine	Director	Buy	3,030	$164.77	$499,253.10
12/6/2017	Brent L. Saunders	Chairman	Buy	4,600	$164.74	$757,804.00
12/5/2017	Christopher J. Coughlin	Director	Buy	10,000	$163.30	$1,633,000.00
12/1/2017	William Meury	Insider	Sell	11,807	$173.89	$2,053,119.23
5/18/2017	Nesli Basgoz	Director	Sell	1,889	$220.45	$416,430.05
3/2/2017	Paul Bisaro	Director	Sell	70,000	$246.68	$17,267,600.00	274,226
12/8/2016	Nesli Basgoz	Director	Sell	500	$188.72	$94,360.00
11/21/2016	Brent L. Saunders	CEO	Buy	5,250	$189.13	$992,932.50
11/11/2016	Maria Teresa Hilado	CFO	Buy	1,422	$210.64	$299,530.08	12,659
6/2/2016	Maria Teresa Hilado	CFO	Buy	661	$241.57	$159,677.77	11,957
5/11/2016	Nesli Basgoz	Director	Sell	459	$225.10	$103,320.90	5,242
12/7/2015	Nesli Basgoz	Director	Sell	2,300	$312.96	$719,808.00	4,062
8/24/2015	Paul Bisaro	Chairman	Buy	1,000	$297.42	$297,420.00	421,755
8/21/2015	Brent L Saunders	CEO	Buy	1,000	$301.94	$301,940.00	132,862
6/9/2015	Nesli Basgoz	Director	Sell	2,200	$297.89	$655,358.00
11/26/2014	William Meury	Insider	Sell	4,550	$269.14	$1,224,587.00
9/8/2014	Albert Paonessa III	Insider	Sell	6,642	$230.49	$1,530,914.58
4/22/2014	Scott Sherman	EVP	Sell	14,500	$155.82	$2,259,390.00	8,223
2/21/2014	Louis Lavigne, Jr.	Director	Sell	5,400	$125.79	$679,266.00	12,723
2/19/2014	Dawn Hudson	Director	Sell	4,200	$126.35	$530,670.00	11,600
2/19/2014	Jeffrey Edwards	CFO	Sell	38,900	$126.39	$4,916,571.00	16,591
2/19/2014	Raymond Diradoorian	EVP	Sell	23,000	$126.66	$2,913,180.00	6,401
2/18/2014	Scott Sherman	EVP	Sell	5,001	$125.74	$628,825.74	8,220
1/14/2014	Scott Whitcup	VP	Sell	42,000	$117.80	$4,947,600.00	17,327
12/27/2013	Julian Gangolli	VP	Sell	52,500	$110.05	$5,777,625.00
12/20/2013	Scott Whitcup	VP	Sell	33,000	$108.80	$3,590,400.00	17,327
10/15/2013	Trevor Jones	Director	Sell	2,000	$90.14	$180,280.00	7,142
9/16/2013	Albert Hummel	Director	Sell	6,200	$137.81	$854,422.00	82,776
9/16/2013	Trevor Jones	Director	Sell	2,000	$89.78	$179,560.00	8,142
9/4/2013	George Fred Wilkinson	Insider	Sell	16,749	$138.00	$2,311,362.00
9/4/2013	Jack Michelson	Director	Sell	6,064	$139.54	$846,170.56
8/29/2013	David Buchen	Insider	Sell	10,000	$135.56	$1,355,600.00	97,373
8/26/2013	Albert Hummel	Director	Sell	40,000	$134.44	$5,377,600.00	92,776
8/20/2013	Paul Bisaro	CEO	Sell	50,000	$135.30	$6,765,000.00	469,232
8/15/2013	Albert Paonessa III	Insider	Sell	5,476	$135.89	$744,133.64	33,812
8/15/2013	Trevor Jones	Director	Sell	2,000	$89.89	$179,780.00	9,142
8/14/2013	R Todd Joyce	CFO	Sell	15,000	$137.98	$2,069,700.00	80,470
8/13/2013	Albert Hummel	Director	Sell	10,000	$133.85	$1,338,500.00	132,776
8/12/2013	Cathy Klema	Director	Sell	1,667	$133.03	$221,761.01	19,608
8/12/2013	David Buchen	Insider	Sell	17,000	$133.03	$2,261,510.00	97,373
8/9/2013	Ronald Taylor	Director	Sell	5,000	$135.14	$675,700.00	27,942
8/6/2013	Jeffrey Edwards	CFO	Sell	69,200	$91.17	$6,308,964.00	16,871
8/5/2013	Charles Ebert	VP	Sell	8,244	$136.25	$1,123,245.00	19,970
8/5/2013	Michel Feldman	Director	Sell	10,000	$136.94	$1,369,400.00	12,941
8/2/2013	Robert Stewart	Insider	Sell	14,564	$136.02	$1,980,995.28	73,891
7/15/2013	Trevor M Jones	Director	Sell	2,000	$91.15	$182,300.00
6/17/2013	Trevor M Jones	Director	Sell	2,000	$101.25	$202,500.00
5/15/2013	Trevor M Jones	Director	Sell	2,000	$103.40	$206,800.00
5/9/2013	Jeffrey L Edwards	CFO	Sell	84,000	$103.49	$8,693,160.00
3/14/2013	Charles M Mayr	Insider	Sell	1,000	$91.77	$91,770.00
3/12/2013	Michael J Fedida	Director	Sell	8,000	$89.00	$712,000.00
11/26/2012	Trevor M Jones	Director	Sell	2,500	$91.30	$228,250.00
10/5/2012	David E I Pyott	CEO	Sell	616,300	$93.73	$57,765,799.00

(Data available from 1/1/2013 forward)

Allergan (NYSE AGN) News Headlines

Source:

Date	Headline
	Vetr Downgrades Allergan (AGN) to Hold www.americanbankingnews.com - April 20 at 9:12 PM
	Allergan (AGN) Upgraded at Vetr www.americanbankingnews.com - April 20 at 5:52 PM
	Allergan: The Shire Deal Is DOA And So Is The Stock seekingalpha.com - April 20 at 3:36 PM
	Allergan Declines to Bid on Shire finance.yahoo.com - April 20 at 3:36 PM
	Allergan Will Not Make Offer for Shire www.bloomberg.com - April 20 at 10:56 AM
	Allergan: What's Going On? seekingalpha.com - April 20 at 10:56 AM
	[$$] Takeda Sweetens Takeover Bid for Shire finance.yahoo.com - April 20 at 10:56 AM
	Allergan Showcases Leadership in Neurosciences with 25 Presentations at the American Academy of Neurology Annual Meeting in Los Angeles www.prnewswire.com - April 20 at 8:10 AM
	Shire retraces on Allergan pass seekingalpha.com - April 19 at 3:37 PM
	CEO of Botox competitor: 'With scale,' we think we'll have the same margins as the market leader www.cnbc.com - April 19 at 3:37 PM
	Allergan Issues Statement Regarding Press Speculation on its Strategic Review www.prnewswire.com - April 19 at 3:37 PM
	CEO of Botox competitor: 'With scale,' we think we'll hav... finance.yahoo.com - April 19 at 3:37 PM
	Allergan will not bid for Shire, sources tell CNBC finance.yahoo.com - April 19 at 3:37 PM
	Allergan Reportedly Enters Fray To Buy Shire, Rivaling Takeda finance.yahoo.com - April 19 at 3:37 PM
	Allergan Weighing Shire Bid Has Investors Worried About Deja Vu finance.yahoo.com - April 19 at 3:37 PM
	Shire rejects $63 billion Takeda bid as Allergan drops pursuit finance.yahoo.com - April 19 at 3:37 PM
	Blink and you missed it: Allergan doesn't plan to make a Shire bid finance.yahoo.com - April 19 at 3:37 PM
	Allergan Does Not Intend to Make an Offer for Shire plc; Strategic Review Continues finance.yahoo.com - April 19 at 3:37 PM
	Allergan Does Not Intend to Make Offer for Shire finance.yahoo.com - April 19 at 3:37 PM
	Allergan (AGN) Confirms Early Stages of Considering Shire (SHPG) Offer, No Offer Has Been Made www.streetinsider.com - April 19 at 10:43 AM
	BRIEF-Allergan Confirms It Is In Early Stages Of Considering Possible Offer For Shire www.reuters.com - April 19 at 10:43 AM
	Allergan in talks to acquire Shire, competing against Takeda Pharmaceutical www.cnbc.com - April 19 at 10:43 AM
	Allergan shares plummet 6% on Shire bid interest, while Shire surges 8% finance.yahoo.com - April 19 at 10:43 AM
	Allergan (AGN) Given Average Rating of "Hold" by Brokerages www.americanbankingnews.com - April 19 at 3:40 AM
	Allergan to Post Q1 2018 Earnings of $3.39 Per Share, SunTrust Banks Forecasts (AGN) www.americanbankingnews.com - April 18 at 7:58 AM
	Stifel Says Allergan Could Use A Face-Lift, Initiates Coverage With Hold finance.yahoo.com - April 17 at 3:43 PM
	New Research Coverage Highlights Exelixis, Verizon Communications, AT&T, Snap, Allergan plc, and QUALCOMM ... globenewswire.com - April 17 at 10:45 AM
	Allergan to pay $3.5 mln over US claims of defective Lap-Bands www.reuters.com - April 17 at 10:45 AM
	Allergan (AGN) Downgraded by Vetr www.americanbankingnews.com - April 17 at 9:25 AM
	Stifel Nicolaus Initiates Coverage on Allergan (AGN) www.americanbankingnews.com - April 17 at 7:39 AM
	Allergan (AGN) Given a $255.00 Price Target at Cowen www.americanbankingnews.com - April 16 at 12:05 PM
	Form DEFA14A Allergan plc www.streetinsider.com - April 16 at 10:27 AM
	Allergan (AGN) Price Target Raised to $278.00 at Wells Fargo www.americanbankingnews.com - April 13 at 6:01 PM
	What does Allergan plc’s (NYSE:AGN) Balance Sheet Tell Us About Its Future? finance.yahoo.com - April 13 at 3:39 PM
	Allergan Announces Launch of the TrueTear® Intranasal Neurostimulation Device During 2018 ASCRS-ASOA Annual ... www.prnewswire.com - April 13 at 11:00 AM
	Pfizer, Allergan Win Out With Tax Benefits www.bloomberg.com - April 12 at 3:40 PM
	Allergan (AGN) Given a $191.00 Price Target at Cantor Fitzgerald www.americanbankingnews.com - April 12 at 3:26 PM
	Allergan (AGN) Earns Outperform Rating from Wells Fargo www.americanbankingnews.com - April 12 at 2:19 PM
	Deutsche Bank Reiterates Buy Rating for Allergan (AGN) www.americanbankingnews.com - April 12 at 11:07 AM
	Allergan (AGN) Downgraded by BidaskClub to "Hold" www.americanbankingnews.com - April 11 at 10:42 PM
	Plaintiffs' Class Counsel Announce Settlement of the Allergan, Inc. Proxy Violation Securities Litigation www.prnewswire.com - April 11 at 11:17 AM
	Global Hyperhidrosis Therapeutics Pipeline Analysis Report 2017 with Key Players Dermira, Allergan and TheraVida ... www.prnewswire.com - April 10 at 3:33 PM
	Allergan Stock Performance in 1Q18 finance.yahoo.com - April 10 at 3:33 PM
	Analyst Recommendations for Teva Pharmaceutical in April 2018 finance.yahoo.com - April 10 at 10:57 AM
	Allergan (AGN) Earns Hold Rating from Cantor Fitzgerald www.americanbankingnews.com - April 10 at 9:17 AM
	Allergan (AGN) Expected to Announce Quarterly Sales of $3.59 Billion www.americanbankingnews.com - April 10 at 2:54 AM
	Biotech Analysis Central Pharma News: Allergan And Richter's Success, Sellas Life Sciences' Breast Cancer Data ... seekingalpha.com - April 9 at 10:54 AM
	$3.35 EPS Expected for Allergan (AGN) This Quarter www.americanbankingnews.com - April 8 at 3:10 PM
	Allergan (AGN) Rating Reiterated by Barclays www.americanbankingnews.com - April 8 at 2:39 PM
	Allergan (AGN) Given a $255.00 Price Target by UBS Analysts www.americanbankingnews.com - April 6 at 10:54 PM

Allergan (NYSE:AGN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Allergan (NYSE:AGN) Income Statement, Balance Sheet and Cash Flow Statement

Allergan (NYSE AGN) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff